Pipeline 2017-04-28T04:22:48+00:00

Product pipeline

Prescient Therapeutics is aggressively pursuing the clinical and commercial development of two novel cancer compounds PTX-200 and PTX-100.

prescient therapeutics pipeline

OUR TRIALS

The Company is conducting a number of clinical trials in the US, and has four open INDs allowed by the US FDA.  PTX-200 is currently undertaking a Phase 2 trial in HER2 negative breast cancer; a Phase 1b trial in relapsed and refractory acute leukemias; and a Phase 1b trial in relapsed and refractory ovarian cancer.

These trials are being conducted at some of the most prestigious cancer centres in the United States.

prescient therapeutics pipeline